Case Reports

Primary anetoderma as a possible preclinical cutaneous clue of Behçet’s disease: evidence suggesting early microvascular-driven dermal elastolysis

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 9 October 2026
32
Views
14
Downloads

Authors

Anetoderma is a rare elastolytic dermatosis characterized by focal loss of dermal elastic fibers leading to localized flaccid, atrophic, or herniated skin lesions. Although it may occur as a primary disorder or secondary to inflammatory dermatoses, infections, or trauma, immune-mediated vascular injury and dysregulation of extracellular matrix remodeling are increasingly recognized as key pathogenetic mechanisms. Behçet’s disease (BD) is a multisystem inflammatory vasculitis driven by neutrophil hyperactivation and endothelial dysfunction, but elastolytic dermatoses have not been included among its classical cutaneous manifestations. We report a 27-year-old man who developed multiple asymptomatic atrophic lesions on the trunk and upper back. Histopathologic examination revealed preserved epidermal architecture and marked loss of elastic fibers in the papillary and mid dermis on Verhoeff-Van Gieson staining, consistent with primary anetoderma. Approximately 3 years later, the patient developed recurrent oral aphthosis, genital ulcers, papulopustular lesions, and a positive pathergy test, fulfilling the International Criteria for Behçet’s Disease. The temporal sequence observed in our patient raises the hypothesis that primary anetoderma may represent a rare early cutaneous manifestation or a preclinical marker of microvascular inflammation in BD. Neutrophil-driven proteolysis and increased matrix metalloproteinase (MMP) activity may contribute to focal dermal elastolysis. Further observations are needed to clarify whether this association reflects a pathogenetic link or a coincidental finding.

Downloads

Download data is not yet available.

Citations

1. Cook JC, Syed HA, Puckett Y. Anetoderma. In: StatPearls [Internet]. StatPearls Publishing; 2026.
2. Alpsoy E. Behçet’s disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol 2016;43:620-32.
3. International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014;28:338-47.
4. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 2018;77:808-18.
5. Stephansson EA, Niemi KM. Antiphospholipid antibodies and anetoderma: are they associated? Dermatology 1995;191:204-9.
6. Venencie PY, Winkelmann RK, Moore BA. Anetoderma. Clinical findings, associations, and long-term follow-up evaluations. Arch Dermatol 1984;120:1032-9.
7. Leccese P, Alpsoy E. Behçet’s Disease: An Overview of Etiopathogenesis. Front Immunol 2019;10:1067.
8. Pay S, Abbasov T, Erdem H, et al. Serum MMP-2 and MMP-9 in patients with Behcet's disease: do their higher levels correlate to vasculo-Behcet's disease associated with aneurysm formation? Clin Exp Rheumatol 2007;25:S70-5.

How to Cite



1.
Primary anetoderma as a possible preclinical cutaneous clue of Behçet’s disease: evidence suggesting early microvascular-driven dermal elastolysis. Dermatol Reports [Internet]. 2026 Oct. 9 [cited 2026 Oct. 12];. Available from: https://journals.pagepress.net/dr/article/view/10871